Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hyperpolarized Xe 129 MRI for Evaluating Bronchodilator Delivery Methods in COPD
NCT06271408Phase 1Active, not recruiting
- Sponsor
- Polarean Imaging
- Start
- Mar 2024
- Primary completion
- Dec 2026
- Countries
- 1
01
Overview
Phase 1, randomised trial of salbutamol in chronic obstructive pulmonary disease (COPD) (3 arms), sponsored by Polarean Imaging. Primary endpoint: Ventilation Defect Percent. Started Mar 2024; status: active, not recruiting.
02
Drugs
salbutamol
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT06271408.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06271408.